Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Mylan Andhra plant...

    Mylan Andhra plant gets USFDA warning over Valsartan manufacturing violations

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-17T10:15:33+05:30  |  Updated On 17 Nov 2019 10:15 AM IST
    Mylan Andhra plant gets USFDA warning over Valsartan manufacturing violations

    The concerns cited by the agency were based on an inspection conducted from May 27, 2019, to June 5, 2019, which placed a primary focus on the manufacturing of Valsartan API.


    New Delhi: The U.S. Food and Drug Administration (FDA) issued a warning letter to drug maker Mylan for “significant deviations” from good manufacturing practices for its manufacturing facility Unit-8 at G. Chodavaram Village, Vizianagaram, Andhra Pradesh, India.


    The concerns cited by the agency were based on an inspection conducted from May 27, 2019, to June 5, 2019, which placed a primary focus on the manufacturing of Valsartan API.


    "We have been working closely with the FDA as well as other global health authorities to investigate all potential risk associated with the ongoing inquiries related to the nitrosamines impurities and always with patient safety as our primary focus," Mylan said in a statement.


    The USFDA warning letter summarized significant deviations from current good manufacturing practise (CGMP) for active pharmaceutical ingredients (API).


    During the USFDA inspection, investigators observed specific deviations including, but not limited to, the following:-




    • Failure to have adequate written procedures for the receipt, identification, testing and handling of raw materials.

    • Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications.


    In a statement, Mylan said that it will be providing a thorough response to the Agency which will detail existing controls in place at the facility to mitigate any perceived risk of product contamination and provide additional enhancements as requested. Mylan’s response will be submitted within the required time period of 15 working days.


    "Of note, extensive testing of APIs manufactured and distributed by the site was performed for the presence of nitrosamine impurities and none were detected. Additionally, an extensive cleaning process and cleaning validation program is in place which is designed to ensure that all the equipment used for manufacturing is cleaned to pre-defined acceptable levels," Mylan added.


    The company further apprised that no interruption in manufacturing or distribution is anticipated at Mylan Laboratories Limited, Unit 8, based on the aforementioned FDA Warning Letter. No significant commercial impact is expected and no significant launches are planned for Unit 8 in 2020.


    Also Read: Mylan, Pfizer say Mylan-Upjohn combined entity to be known as Viatris
    cGMPcgmp violationForm FDA 483MylanN-nitrosodiethylamineNDMAsignificant violationUSFDAUSFDA warningValsartanwarning letter

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok